HIGHLIGHTS
- who: Tamara K. Moyo from the Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Pierce Nashville, TN , PRB, USA have published the research: The ABNL-MARRO 001 study: a randomized phase 1-2 study of active myeloid target compound combinations in MDS/MPN overlap syndromes, in the Journal: (JOURNAL) of August/19,/2019
- what: The aims for the study are to characterize the dose limiting toxicities of novel oral targeted agents in combination with oral ASTX727 (Phase 1) and to test whether the overall response to each therapy warrants further investigation in more definitive . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.